Theravance Biopharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Theravance Biopharma, Inc. (TBPH) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $20.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-23
- Theravance Biopharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $20.86M.
- Theravance Biopharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$46.63M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $20.86M 10-K · filed 2026-03-23 |
| 2024-12-31 | -$46.63M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |